newsfilter
← Latest News
GlobeNewswire·

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately